Global News

EntreMed initiates phase II trial in advanced/metastatic soft tissue sarcoma

Friday, January 25, 2013 01:11 PM

EntreMed, a clinical-stage pharmaceutical company, has initiated a single-center phase II study of oral ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma at Princess Margaret Hospital where the study is led by Malcolm Moore, MD and Albiruni R.A. Razak, MD.

More... »

CDISC names additions to board of directors

Friday, January 25, 2013 12:27 PM

CDISC, a global, open, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata, has named five highly qualified individuals that will add invaluable expertise to the CDISC board of directors (BoD) for a three-year term beginning this month (2013–2016): Dr. Carolyn Compton, Michael Glickman, Dr. Douglas Peddicord, Stephen Pyke and John Speakman.

More... »

Gilead initiates phase III program for tenofovir alafenamide for HIV

Friday, January 25, 2013 11:30 AM

Gilead Sciences, a biopharmaceutical company based in Foster City, Calif., has initiated the first of two phase III clinical trials (Study 104) evaluating a single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults.

More... »

Ipsen, Inspiration enter into asset purchase agreement with Baxter on OBI-1

Friday, January 25, 2013 10:32 AM

Ipsen, a global specialty-driven pharmaceutical company, and Inspiration Biopharmaceuticals, a biopharmaceutical company focused on hemophilia, have entered into an Asset Purchase Agreement (APA) whereby healthcare company Baxter International will acquire worldwide rights to OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital hemophilia A with inhibitors and acquired hemophilia A, and Ipsen's industrial facility in Milford, Mass.

More... »

ReCor receives CE mark for ultrasound-based renal denervation system

Thursday, January 24, 2013 02:00 PM

ReCor Medical, a private venture-backed, early-stage company focused on ultrasound catheter technology, has received CE mark for its next-generation Paradise system, a minimally invasive 6Fr over-the-wire (OTW) ultrasound device for treating resistant high blood pressure.

More... »

Recordati finalizes acquisition of portfolio from Lundbeck

Wednesday, January 23, 2013 11:25 AM

Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.

More... »

Xceleron, Crystal Pharmatech to improve early clinical development

Wednesday, January 23, 2013 09:59 AM

Xceleron, a Germantown, Md.-based CRO that applies ultra-sensitive analytical technology to novel clinical designs, has formed a partnership with Crystal Pharmatech, a China-based technology-driven research CRO.

More... »

Watson acquires Uteron Pharma

Wednesday, January 23, 2013 09:30 AM

Watson Pharmaceuticals, a global, integrated specialty generics pharmaceutical company, has completed the acquisition of Belgium-based Uteron Pharma, a development-based company dedicated to female healthcare, for $150 million in cash up front, and up to $155 million in potential future milestone payments. 

More... »

Cancer Research U.K. and Astex’s CRT initiate AT13148 trial for cancer

Friday, January 18, 2013 03:18 PM

Cancer Research Technology (CRT), the commercial arm of Astex Pharmaceuticals, a pharmaceutical company focused on novel small molecule therapeutics, along with its collaborator Cancer Research U.K., has initiated a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death.

More... »

InDevR spins off ViroCyt, raises growth capital

Wednesday, January 16, 2013 11:50 AM

ViroCyt, a privately held life science company, has begun operations after spinning off from InDevR, a developer of advanced life science instrumentation and assays. Concurrent with the formation of ViroCyt, funding was secured from a group of investors led by High Country Venture.

More... »